At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; BTG
- Class Anti-inflammatories; Antipsoriatics; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 10 Jul 2002 No development reported - Preclinical for Psoriasis in USA (Topical)
- 12 Oct 1999 Preclinical studies have been added to the pharmacokinetics and adverse events sections (Company communication, BTG International, November 1998)